PremiumThe FlyXenetic enters clinical trial services agreement with PeriNess Xenetic presents preclinical data on DNase I with CAR T cells in murine model Xenetic reports Q3 EPS (28c) vs. (69c) last year PremiumThe FlyXenetic files $50M mixed securities shelf Xenetic enters into material transfer agreement with Tokyo Medical University Xenetic reports Q2 EPS (83c) vs. (69c) last year PremiumCompany AnnouncementsXenetic Biosciences, Inc. Under Pressure: Shareholder Activism Threatens Stability and Financial Future Xenetic Biosciences Shares Insights on Oncology Platform Xenetic enters research agreement with University of Virginia 
